About this episode

The episode discusses treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure.

Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies. Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes. Learning Objectives Understand mechanisms of resistance and progression following BCMA-targeted therapy. Explore non-BCMA treatment options, including alternative targets and novel agents. Recognize key factors influencing treatment selection and patient management.

People in this episode

Guests: Dr. Natalia Neparidze, Dr. Saad Z. Usmani

Topics covered

• relapsed myeloma
• BCMA therapy failure
• treatment strategies
• CAR T-cell therapy
• novel agents
• patient management

Keywords

• relapsed myeloma
• BCMA-targeted therapy
• treatment sequencing
• mechanisms of resistance
• novel agents
• patient outcomes

Mentioned in this episode

Organizations: American Society of Hematology

Products: CAR T-cell therapy, bispecific antibodies, selinexor-pomalidomide-dexamethasone

Places: BCMA, multiple myeloma

More episodes of HemeTalks: Conversations in Hematology Education

• Approaching MDS: Advances in Diagnostics, Therapeutics and Monitoring · April 16, 2026 · 25 min
• New Horizons in Smoldering Multiple Myeloma · March 19, 2026 · 26 min
• Interpreting Abnormal SPEP – Is It Just MGUS? · February 19, 2026 · 27 min
• Sticky Situations: The Role of Thrombophilia Testing in VTE Management · January 15, 2026 · 28 min
• Lost in Translation: The aHUS Experience · December 18, 2025 · 20 min
• Inclusion of those with those with Duffy-null Associated Neutrophil Count (DANC) in Clinical Trials · November 20, 2025 · 26 min

Explore listener stats, chart rankings, contacts and more on the HemeTalks: Conversations in Hematology Education podcast page.